Healthcare Industry News: Medarex
News Release - February 4, 2016
Lion Biotechnologies Names Steven A. Fischkoff Chief Medical OfficerNEW YORK, NY--(Healthcare Sales & Marketing Network) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Steven A. Fischkoff, MD, as chief medical officer (CMO), effective immediately.
With 25 years of biopharmaceutical experience, Dr. Fischkoff most recently served as vice president of clinical and medical affairs at Celgene Cellular Therapeutics, where his responsibilities included the development of cell based products for the treatment of malignant and non-malignant diseases. Previously he was vice president of clinical development at Palatin Technologies, and he has also held senior clinical positions at Medarex, Inc. and Knoll Pharmaceuticals/Abbott Laboratories.
Prior to joining the industry, Dr. Fischkoff spent 15 years in academic positions at the National Cancer Institute and the medical schools of the University of Maryland and the University of Pennsylvania. He holds an MD from the University of Pennsylvania.
"Steven brings to Lion a deep knowledge of the immuno-oncology space, combined with a broad range of clinical, management and regulatory experience," said Elma Hawkins, PhD, Lion's president and CEO. "We are very pleased to welcome him to our management team and look forward to his medical leadership as we continue to advance and expand our clinical pipeline."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma. The company is also pursuing the use of its products in other cancer indications including cervical, and head and neck squamous cell carcinoma (HNSCC). The company's therapies are based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Lion Biotechnologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.